Functional assessment of miR1291 in colon cancer cells

Jiaqi Wang1, Yuhki Yokoyama1, Haruka Hirose1

  • 1Department of Molecular Pathology, Division of Health Sciences, Osaka University, Suita, Osaka 565‑0871, Japan.

Insights

MicroRNA-1291 (miR-1291) inhibits colorectal cancer (CRC) growth by targeting doublecortin-like kinase 1 (DCLK1), suppressing cancer stemness and regulating cell cycle. This suggests miR-1291 as a potential therapeutic for CRC.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • The role of microRNA-1291 (miR-1291) in colorectal cancer (CRC) remains largely unexplored, despite its known anti-tumor effects in other carcinomas.
  • Understanding miR-1291's function in CRC is crucial for developing novel therapeutic strategies.

Purpose of the Study:

  • To investigate the expression and anti-tumor effects of miR-1291 in colorectal cancer cells.
  • To identify the molecular targets and mechanisms underlying miR-1291's action in CRC.

Main Methods:

  • Luciferase reporter assays to confirm direct binding of miR-1291 to DCLK1.
  • Cell proliferation, invasion, migration, apoptosis, and sphere formation assays in CRC cell lines.
  • Western blotting and RT-qPCR to assess DCLK1, BMI1, CD133, p21, and p27 expression.
  • In vivo studies using a DLD-1 xenograft mouse model with a novel drug delivery system.

Main Results:

  • miR-1291 significantly suppressed CRC cell proliferation, invasion, migration, and colony formation, while inducing apoptosis.
  • miR-1291 directly targets and downregulates doublecortin-like kinase 1 (DCLK1) expression.
  • miR-1291 inhibited cancer stem cell markers (BMI1, CD133) and sphere formation, effects partially mediated by DCLK1.
  • miR-1291 induced cell cycle inhibitors p21 and p27, and its administration in vivo reduced tumor growth.

Conclusions:

  • miR-1291 exhibits potent anti-tumor activity in colorectal cancer by targeting DCLK1.
  • miR-1291 modulates cancer stemness and cell cycle regulation, highlighting its potential as a therapeutic agent.
  • miR-1291 represents a promising nucleic acid-based therapeutic candidate for colorectal cancer treatment.

Related Concept Videos